PubMed Health⌕ Search

Biomedical subjects

C H Mason

Publications and source records attributed to C H Mason.

16 recordsLinked to original sources
PubMed2003

Adenomyoepithelioma of the breast: spectrum of disease with associated imaging and pathology.

OBJECTIVE: Our objective was to show the spectrum of biologic behavior associated with breast adenomyoepithelioma. This disease is a rare benign breast neoplasm characterized by proliferation of both epithelial and myoepithelial cellular elements. Malignant change of one or both cell types may occur and is thought to be associated with hematogenous, rather than lymphatic, metastasis. CONCLUSION: Three patients with benign and malignant adenomyoepithelioma were included in this study. The imaging and histopathologic findings in these three patients are illustrated, and the treatment of patients with this unusual tumor is discussed.

Aged↗
PubMed1995

Combined goblet cell carcinoid and mucinous cystadenoma of the appendix.

Two cases of combined goblet cell carcinoid and mucinous cystadenoma occurring in the appendix are reported. The histogenesis of the goblet cell carcinoid remains one of its most controversial aspects and the occurrence of both of these relatively uncommon tumours in the same organ may lend support to the unitary stem cell hypothesis on the origin of this tumour. Alternatively, this occurrence may represent an example of the adenoma/carcinoma sequence.

Appendiceal Neoplasms↗
PubMed1989

A perspex grid for localization of non-palpable mammographic lesions in breast biopsies.

The examination of excised, non-palpable mammographic lesions in breast biopsies is a recognized problem for the pathologist. There may be difficulties in identifying the lesion macroscopically and in subsequent sampling. This paper describes a simple method for resolving these problems. The breast biopsy is attached to a perspex grid and then radiographed. Use of the grid co-ordinates assists appropriate sampling of the specimen. Advantages over previously described methods are discussed.

Biopsy↗
PubMed1989

Brown bowel syndrome: an unusual cause of massive dilatation of the colon.

We report a case of the brown bowel syndrome presenting as major dilatation of the colon which resembled 'toxic dilatation' and necessitated subtotal colectomy. We confirm the reported association between the brown bowel syndrome, malabsorption, and hypovitaminosis E. Furthermore we document failure of the brown pigmentation to resolve after six months in spite of vitamin E supplements and correction of the malabsorption. Finally we suggest that, although the brown bowel syndrome is rare, it should be considered in cases of major colonic dilatation where the patient is or may be suffering from a malabsorption syndrome, and where the sigmoidoscopic appearances do not suggest severe inflammatory bowel disease.

Adult↗
PubMed1988

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

One hundred and sixty four patients with ulcerative colitis in remission were entered into a double blind, double dummy trial comparing olsalazine 500 mg bd and sulphasalazine 1 g bd. Clinical examination, sigmoidoscopy and rectal biopsy were performed at 0, three, and six months. Sixteen of 82 (19.5%) patients relapsed on olsalazine and 10/82 (12.2%) relapsed on sulphasalazine. The difference was not statistically significant (p = 0.1632). Adverse events were minor and were similar in both groups. No haematological or biochemical abnormalities were detected. Thus, olsalazine is as effective as sulphasalazine for preventing a relapse of ulcerative colitis.

Adolescent↗
PubMed1985

Olsalazine in active ulcerative colitis.

Olsalazine (azodisalicylate) is a new drug in which two molecules of 5-aminosalicylic acid are linked by an azo bond. Its role in the treatment of mildly active, distal ulcerative colitis was investigated. Sixty patients were randomly allocated to receive olsalazine 1 g or a placebo as a retention enema nightly for two weeks. Clinical improvement was seen in 19 (66%) and sigmoidoscopic improvement in 17 (59%) of the 29 patients receiving olsalazine compared with 12 (43%) and 11 (39%), respectively, of the 28 in the control group. These differences were not significant. In a second trial 40 patients were randomised to receive oral olsalazine 2 g daily or a placebo capsule for two weeks. Significant clinical and sigmoidoscopic improvement was seen in the patients receiving oral olsalazine compared with the patients receiving placebo capsules. Oral olsalazine may be valuable in the treatment of mildly active ulcerative colitis. Its role in maintaining remission is yet to be determined.

Administration, Oral↗